Peter Savas
Peter MacCallum Cancer Centre
11 Papers
13 Citations
Peter Savas is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 5, co-authored 11 publications. Previous affiliations of Peter Savas include University of Melbourne.
Chat about Author
Papers
Pervasive chromosomal instability and karyotype order in tumour evolution.
Thomas B.K. Watkins,Emilia L. Lim,Emilia L. Lim,Marina Petkovic,Sergi Elizalde,Nicolai Juul Birkbak,Nicolai Juul Birkbak,Nicolai Juul Birkbak,Gareth A. Wilson,David Allan Moore,Eva Grönroos,Andrew Rowan,Sally M. Dewhurst,Jonas Demeulemeester,Jonas Demeulemeester,Stefan C. Dentro,Stefan C. Dentro,Stefan C. Dentro,Stuart Horswell,Lewis Au,Lewis Au,Kerstin Haase,Mickael Escudero,Rachel Rosenthal,Rachel Rosenthal,Maise Al Bakir,Hang Xu,Kevin Litchfield,Wei-Ting Lu,Thanos P. Mourikis,Michelle Dietzen,Lavinia Spain,Lavinia Spain,George D. Cresswell,Dhruva Biswas,Dhruva Biswas,Philippe Lamy,Iver Nordentoft,Katja Harbst,Francesc Castro-Giner,Francesc Castro-Giner,Lucy R. Yates,Lucy R. Yates,Franco Caramia,Fanny Jaulin,Cecile Vicier,Ian Tomlinson,Priscilla K. Brastianos,Priscilla K. Brastianos,Raymond J. Cho,Boris C. Bastian,Lars Dyrskjøt,Göran Jönsson,Peter Savas,Peter Savas,Sherene Loi,Sherene Loi,Peter J. Campbell,Fabrice Andre,Fabrice Andre,Nicholas M. Luscombe,Nicholas M. Luscombe,Nicholas M. Luscombe,Neeltje Steeghs,Vivianne C. G. Tjan-Heijnen,Zoltan Szallasi,Zoltan Szallasi,Samra Turajlic,Samra Turajlic,Mariam Jamal-Hanjani,Peter Van Loo,Samuel F. Bakhoum,Roland F. Schwarz,Roland F. Schwarz,Nicholas McGranahan,Charles Swanton,Charles Swanton +76 more
TL;DR: Multi-sample phasing and SCNA analysis of 1,421 samples from 394 tumours across 22 tumour types are used to show that continuous chromosomal instability results in pervasive SCNA heterogeneity.
344
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Zuzana Kos,Elvire Roblin,Rim S. Kim,Stefan Michiels,Brandon D. Gallas,Weijie Chen,Koen Van de Vijver,Shom Goel,Shom Goel,Sylvia Adams,Sandra Demaria,Giuseppe Viale,Torsten O. Nielsen,Sunil S. Badve,W. Fraser Symmans,Christos Sotiriou,David L. Rimm,Stephen M. Hewitt,Carsten Denkert,Sibylle Loibl,Stephen J Luen,Stephen J Luen,John M. S. Bartlett,John M. S. Bartlett,Peter Savas,Peter Savas,Giancarlo Pruneri,Deborah A. Dillon,Deborah A. Dillon,Maggie C.U. Cheang,Andrew Tutt,Jacqueline A. Hall,Marleen Kok,Hugo M. Horlings,Anant Madabhushi,Anant Madabhushi,Jeroen van der Laak,Francesco Ciompi,Anne Vibeke Lænkholm,Enrique Bellolio,Tina Gruosso,Stephen B. Fox,Juan Carlos Araya,Giuseppe Floris,Jan Hudecek,Leonie Voorwerk,Andrew H. Beck,Jen Kerner,Denis Larsimont,Sabine Declercq,Gert Van den Eynden,Lajos Pusztai,Anna Ehinger,Wentao Yang,Khalid AbdulJabbar,Yinyin Yuan,Rajendra Singh,Crispin T. Hiley,Maise Al Bakir,Alexander J. Lazar,Stephen P. Naber,Stephan Wienert,Miluska Castillo,Giuseppe Curigliano,Maria Vittoria Dieci,Fabrice Andre,Charles Swanton,Charles Swanton,Jorge S. Reis-Filho,Joseph A. Sparano,Eva Balslev,I-Chun Chen,Elisabeth Specht Stovgaard,Katherine L. Pogue-Geile,Kim Blenman,Frédérique Penault-Llorca,Stuart J. Schnitt,Sunil R. Lakhani,Anne Vincent-Salomon,Federico Rojo,Jeremy P Braybrooke,Matthew G. Hanna,M. Teresa Soler-Monsó,Daniel Bethmann,Carlos A. Castaneda,Karen Willard-Gallo,Ashish Sharma,Huang-Chun Lien,Susan Fineberg,Jeppe Thagaard,Laura Comerma,Paula I. Gonzalez-Ericsson,Edi Brogi,Sherene Loi,Sherene Loi,Joel H. Saltz,Frederick Klaushen,Lee Cooper,Mohamed Amgad,David Moore,Roberto Salgado +100 more
- 12 May 2020
TL;DR: Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to affect treatment selection if cutpoints are employed.
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
Mohamed Amgad,Elisabeth Specht Stovgaard,Eva Balslev,Jeppe Thagaard,Weijie Chen,Sarah N Dudgeon,Ashish Sharma,Jennifer K. Kerner,Carsten Denkert,Carsten Denkert,Carsten Denkert,Yinyin Yuan,Khalid AbdulJabbar,Stephan Wienert,Peter Savas,Peter Savas,Leonie Voorwerk,Andrew H. Beck,Anant Madabhushi,Anant Madabhushi,Johan Hartman,Manu M. Sebastian,Hugo M. Horlings,Jan Hudecek,Francesco Ciompi,David Moore,Rajendra Singh,Elvire Roblin,Marcelo Luiz Balancin,Marie-Christine Mathieu,Jochen K. Lennerz,Pawan Kirtani,I-Chun Chen,Jeremy P Braybrooke,Jeremy P Braybrooke,Giancarlo Pruneri,Sandra Demaria,Sylvia Adams,Stuart J. Schnitt,Sunil R. Lakhani,Federico Rojo,Laura Comerma,Sunil S. Badve,Mehrnoush Khojasteh,W. Fraser Symmans,Christos Sotiriou,Paula I. Gonzalez-Ericsson,Katherine L. Pogue-Geile,Rim S. Kim,David L. Rimm,Giuseppe Viale,Stephen M. Hewitt,John M. S. Bartlett,John M. S. Bartlett,Frédérique Penault-Llorca,Shom Goel,Huang-Chun Lien,Sibylle Loibl,Zuzana Kos,Sherene Loi,Sherene Loi,Matthew G. Hanna,Stefan Michiels,Stefan Michiels,Marleen Kok,Torsten O. Nielsen,Alexander J. Lazar,Zsuzsanna Bago-Horvath,Loes F. S. Kooreman,Jeroen van der Laak,Jeroen van der Laak,Joel H. Saltz,Brandon D. Gallas,Uday Kurkure,Michael Barnes,Roberto Salgado,Lee Cooper +76 more
- 12 May 2020
TL;DR: The benefits of computational TILs assessment, the readiness of Tils scoring for computational assessment, and considerations for overcoming key barriers to clinical translation in this arena are outlined.
136
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
TL;DR: Tumor-infiltrating lymphocytes are gaining increasing relevance as an immunological biomarker in this arena as discussed by the authors, with the use of immunotherapy in the first-line metastatic setting in those who are programmed death ligand 1-positive (Lancet Oncol 2020;21(1):44-59).
15
Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Jennifer Mooi,Fiona Chionh,Peter Savas,Jessica Da Gama Duarte,Geoffrey Chong,Stephen L. Brown,Rachel Wong,Timothy J. Price,Timothy J. Price,Alysson Wann,Effie Skrinos,John M. Mariadason,Niall C. Tebbutt +12 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC).